TYPE 1 DIABETES GENETIC RISK

Type 1 Diabetes Genetic Risk — HLA haplotypes that account for half of all T1D genetic susceptibility, identifying children at 10-20x elevated risk who can now access prevention trials before autoimmunity eliminates beta cell function.

Whole genome sequencing provides complete HLA-DR/DQ typing — the primary genetic determinants of T1D risk — alongside polygenic risk score variants, enabling stratification of at-risk children for prevention programs and screening in the era of teplizumab.

HLA-DRB1
HLA-DQA1
HLA-DQB1
INS
PTPN22

About this condition

Type 1 Diabetes — Genetic Risk

Type 1 diabetes (T1D) is an autoimmune disease in which T cell-mediated destruction of pancreatic beta cells results in absolute insulin deficiency. T1D has a strong but complex genetic architecture — heritability is approximately 80%, but penetrance is incomplete, reflecting substantial non-genetic (environmental and infectious) disease modifiers. HLA class II genes account for approximately 40-50% of total T1D genetic risk. The highest-risk HLA haplotype combinations — particularly DR3-DQ2 (HLA-DRB1*03:01-DQA1*05:01-DQB1*02:01) and DR4-DQ8 (HLA-DRB1*04-DQA1*03:01-DQB1*03:02) — confer dramatically elevated lifetime T1D risk when inherited in combination.

Children who are DR3/DR4 compound heterozygous (one DR3-DQ2 haplotype and one DR4-DQ8 haplotype) have an approximately 5-10% lifetime risk of T1D — compared to approximately 0.4% in the general population. First-degree relatives of T1D patients with the DR3/DR4 genotype have even higher absolute risk, approaching 15-25% lifetime. HLA-protective haplotypes — particularly HLA-DRB1*15:02 (DR15) paired with DQ6 — substantially reduce T1D risk even when present alongside risk alleles. Additional non-HLA loci (INS, PTPN22, CTLA4, IL2RA/CD25) contribute modest individual effects but substantial combined polygenic risk.

The 2022 FDA approval of teplizumab (Tzield) — an anti-CD3 monoclonal antibody that delayed T1D onset by a median of 2+ years in high-risk individuals with multiple autoantibodies in the TrialNet study — has transformed the clinical utility of T1D genetic risk stratification. High-risk HLA individuals can now be followed with islet autoantibody screening (stage 1 presymptomatic T1D identification), and those with 2+ autoantibodies qualify for teplizumab — the first disease-modifying therapy to delay or potentially prevent clinical T1D. This makes genetic risk stratification in children and siblings of T1D patients directly actionable in a way that was not possible before 2022.

Monogenic diabetes (MODY) — caused by single-gene variants in GCK, HNF1A, HNF4A, and other beta cell transcription factor genes — can mimic early-onset T1D but requires a completely different management approach. Distinguishing T1D from MODY requires complete molecular evaluation.

Gene locus: HLA-DRB1, HLA-DQA1, HLA-DQB1 (6p21.32); INS (11p15.5); PTPN22 (1p13.2)

HLA typing for T1D risk stratification requires high-resolution 4-digit class II allele determination. Whole genome sequencing provides complete HLA-DR/DQ haplotyping alongside polygenic risk score variants and MODY gene evaluation in a single test.

Identifying high-risk HLA enables access to teplizumab prevention — and autoantibody monitoring before symptoms

Teplizumab eligibility requires stage 2 presymptomatic T1D diagnosis — the presence of 2 or more islet autoantibodies and abnormal glucose tolerance. Identifying stage 2 T1D requires systematic autoantibody monitoring, which is targeted toward individuals known to be at elevated genetic risk. Without HLA risk stratification, this monitoring happens only in first-degree relatives of T1D patients (who receive TrialNet screening) — the much larger population of genetically at-risk individuals with no T1D family history is not systematically identified. Whole genome sequencing–based HLA typing can identify these high-risk individuals and prompt autoantibody screening and TrialNet enrollment.

Whole genome sequencing simultaneously evaluates MODY genes — distinguishing T1D from treatable monogenic diabetes

Maturity-onset diabetes of the young (MODY) — caused by single heterozygous variants in GCK, HNF1A, HNF4A, HNF1B, and other genes — is frequently misdiagnosed as type 1 or type 2 diabetes. MODY accounts for approximately 1-2% of all diabetes diagnoses but may represent up to 5-10% of young-onset diabetes cases. The clinical distinction is critical: GCK-MODY typically requires no treatment; HNF1A and HNF4A-MODY are exquisitely sensitive to sulfonylureas and may not require insulin. Whole genome sequencing evaluates HLA haplotypes for T1D risk alongside complete MODY gene panel sequencing — a combination that resolves the diagnostic ambiguity in atypical young-onset diabetes presentations.

Type 1 Diabetes Genetic Risk — HLA haplotypes that account for half of all T1D genetic susceptibility, identifying children at 10-20x elevated risk who can now access prevention trials before autoimmunity eliminates beta cell function.

Type 1 Diabetes — Genetic Risk

HLA typing for T1D risk stratification requires high-resolution 4-digit class II allele determination. Whole genome sequencing provides complete HLA-DR/DQ haplotyping alongside polygenic risk score variants and MODY gene evaluation in a single test.

Identifying high-risk HLA enables access to teplizumab prevention — and autoantibody monitoring before symptoms

Whole genome sequencing simultaneously evaluates MODY genes — distinguishing T1D from treatable monogenic diabetes

Others in Autoimmune & Inflammatory

One test. A lifetime of answers.